You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Immunotherapy, A2aR, PDR001, NIR178, NSCLC, solid tumors

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma, Prostate Cancer, Ovarian Cancer Trial in United States (Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or

Active, not recruiting
  • Melanoma
  • +8 more
  • Los Angeles, California
  • +9 more
Nov 15, 2022

Metastatic Extracranial Malignant Solid Tumor, Radiotherapy, Immune Checkpoint Blockade Trial in Shantou (Intestinal Low Dose

Not yet recruiting
  • Metastatic Extracranial Malignant Solid Neoplasm
  • +3 more
  • Intestinal Low Dose Radiotherapy-1Gy
  • +3 more
  • Shantou, Guangdong, China
    Cancer Hospital, Shantou University Medical College
Oct 7, 2023

Tumor Trial in China, Korea, Republic of, Taiwan (Erdafitinib)

Active, not recruiting
  • Neoplasm
  • Beijing, China
  • +5 more
Jan 31, 2023

Efficacy, Safety Trial (PD-L1 inhibitor)

Not yet recruiting
  • Efficacy
  • Safety
  • PD-L1 inhibitor
  • (no location specified)
Apr 6, 2022

LMV-12 Combined With Osimertinib in NSCLC

Not yet recruiting
  • Non Small Cell Lung Cancer
  • LMV-12(HE003) and Osimertinib
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Oct 25, 2023

Tumor Vaccines for Solid Tumors

Recruiting
  • Glioma
  • Solid Tumor
  • tumor vaccine
  • +3 more
  • Shanghai, Shanghai, China
    Huashan Hospital, Fudan University
Oct 22, 2023

Solid Tumor, Adult, Colorectal Cancer, NSCLC Trial in United States (A2B694, xT CDx with HLA-LOH Assay)

Not yet recruiting
  • Solid Tumor, Adult
  • +19 more
  • A2B694
  • xT CDx with HLA-LOH Assay
  • Duarte, California
  • +9 more
Sep 22, 2023

Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer, HER2-Negative Breast Cancer, Metastatic Epithelial Ovarian Cancer

Terminated
  • Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer
  • +2 more
  • Boston, Massachusetts
  • +2 more
Mar 16, 2022

Lung Cancer, Non-small Cell Trial in Nanjing (hypofractionated radiation therapy)

Active, not recruiting
  • Lung Cancer, Non-small Cell
  • hypofractionated radiation therapy
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Hospital
Mar 13, 2023

Lung Cancer Trial (Sacituzumab Govitecan, Pembrolizumab)

Not yet recruiting
  • Lung Cancer
  • (no location specified)
Sep 20, 2023

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Chang chun

Not yet recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +3 more
  • Chang chun, Jilin, China
    Jinlin Province Cancer Hosipital
Dec 21, 2022

Metastatic Pancreatic Adenocarcinoma Trial in United States (Nivolumab (Cohort A), Ipilimumab (Cohort A and B),

Active, not recruiting
  • Metastatic Pancreatic Adenocarcinoma
  • Nivolumab (Cohort A)
  • +4 more
  • Los Angeles, California
  • +6 more
Aug 8, 2022

Advanced Solid Tumors, Metastatic Solid Tumors Trial in Duarte, Cheongju-si (GDC-1971, Atezolizumab, Omeprazole)

Recruiting
  • Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Duarte, California
  • +1 more
Aug 10, 2022

Non-small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal SCC Trial in Worldwide (TNO155, Spartalizumab,

Recruiting
  • Non-small Cell Lung Carcinoma
  • +4 more
  • Boston, Massachusetts
  • +8 more
Mar 18, 2022

Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma Trial in

Active, not recruiting
Has Results
  • Metastatic Melanoma
  • +22 more
  • Ipilimumab
  • +3 more
  • Birmingham, Alabama
  • +24 more
Jan 19, 2023

Non Small Cell Lung Cancer, Locally Advanced, Radiotherapy Trial in Wuhan (CTV omitted or delineated)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • CTV omitted or delineated
  • Wuhan, Hubei, China
    Hubei Cancer Hospital
Sep 1, 2023

Prediction in Solid Tumors

Recruiting
  • Malignant Solid Neoplasm
  • Biospecimen Collection
  • Questionnaire Administration
  • Ames, Iowa
  • +5 more
Sep 7, 2022

Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or

Completed
  • Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
  • Avelumab Phase 1b
  • +3 more
  • Fayetteville, Arkansas
  • +57 more
Jan 18, 2023

Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Tumor Trial in Canada,

Active, not recruiting
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • +20 more
  • Pembrolizumab
  • Ziv-Aflibercept
  • Tampa, Florida
  • +8 more
Jan 3, 2023

Omitting Clinical Target Volume in Radical Treatment of

Not yet recruiting
  • Immunotherapy
  • +3 more
  • IMRT+adjuvant immunotherapy
  • (no location specified)
Jun 9, 2023

Solid Tumor Trial (IN10018, Nab-paclitaxel, Tislelizumab)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Aug 1, 2023

Response Rate in Patients With Advanced NSCLC on ICI

Recruiting
  • Non Small Cell Lung Cancer Metastatic
  • Diabetes Mellitus
  • Pembrolizumab
  • Assiut, Egypt
    Assiut university
Oct 20, 2023

Lung Cancer, Stage III Lung Cancer, Unresectable Lung Carcinoma Trial in Barcelona (procedure, diagnostic test, drug)

Recruiting
  • Lung Cancer
  • +2 more
  • Sample collection
  • +3 more
  • Barcelona, Spain
    Parc de Salut Mar - Hospital del Mar
Dec 8, 2022

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

Active, not recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +39 more
  • pralsetinib (BLU-667)
  • Phoenix, Arizona
  • +65 more
Nov 10, 2022

NSCLC Trial in Worldwide (PDR001, Cisplatin, Gemcitabine)

Terminated
  • Non-small Cell Lung Cancer
  • Fayetteville, Arkansas
  • +22 more
Aug 11, 2022